Mark P DeAndrade1, Amy Trongnetrpunya2, Fumiaki Yokoi1, Chad C Cheetham3, Ning Peng4, J Michael Wyss4, Mingzhou Ding2, Yuqing Li1. 1. Department of Neurology, College of Medicine,, College of Medicine, University of Florida, Gainesville, Florida, USA. 2. J. Crayton Pruitt Family Department of Biomedical Engineering, Herbert Wertheim College of Engineering, University of Florida, Gainesville, Florida, USA. 3. Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 4. Department of Cell, Developmental, and Integrative Biology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
INTRODUCTION: DYT1 dystonia is an autosomal-dominant movement disorder characterized by abnormal, often repetitive, movements and postures. Its hallmark feature is sustained or intermittent contractions of muscles involving co-contractions of antagonist muscle pairs. The symptoms are relieved with the anticholinergic drug trihexyphenidyl. The primary mutation is a trinucleotide deletion (ΔGAG) in DYT1/TOR1A, which codes for torsinA. Previous studies showed that (1) heterozygous Dyt1 ΔGAG knock-in mice, which have an analogous mutation in the endogenous gene, exhibit motor deficits and altered corticostriatal synaptic plasticity in the brain and (2) these deficits can be rescued by trihexyphenidyl. However, brain imaging studies suggest that the Dyt1 knock-in mouse models nonmanifesting mutation carriers of DYT1 dystonia. The aim of this work was to examine the hallmark features of DYT1 dystonia in the Dyt1 knock-in mice by analyzing muscular activities. METHODS: Wireless telemetry devices with biopotential channels were implanted to the bicep and the rectus femori muscles in Dyt1 knock-in mice, and muscular activities were recorded before and after trihexyphenidyl administration. RESULTS: (1) Consistent with DYT1 dystonia patients, Dyt1 knock-in mice showed sustained contractions and co-contractions of the antagonistic bicep femoris and rectus femoris. (2) The abnormal muscle contractions were normalized by trihexyphenidyl. CONCLUSION: The results suggest that the motor deficits in Dyt1 knock-in mice are likely produced by abnormal muscle contractions, and Dyt1 knock-in mice can potentially be used as a manifesting disease model to study pathophysiology and develop novel therapeutics.
INTRODUCTION:DYT1 dystonia is an autosomal-dominant movement disorder characterized by abnormal, often repetitive, movements and postures. Its hallmark feature is sustained or intermittent contractions of muscles involving co-contractions of antagonist muscle pairs. The symptoms are relieved with the anticholinergic drug trihexyphenidyl. The primary mutation is a trinucleotide deletion (ΔGAG) in DYT1/TOR1A, which codes for torsinA. Previous studies showed that (1) heterozygous Dyt1 ΔGAG knock-in mice, which have an analogous mutation in the endogenous gene, exhibit motor deficits and altered corticostriatal synaptic plasticity in the brain and (2) these deficits can be rescued by trihexyphenidyl. However, brain imaging studies suggest that the Dyt1 knock-in mouse models nonmanifesting mutation carriers of DYT1 dystonia. The aim of this work was to examine the hallmark features of DYT1 dystonia in the Dyt1 knock-in mice by analyzing muscular activities. METHODS: Wireless telemetry devices with biopotential channels were implanted to the bicep and the rectus femori muscles in Dyt1 knock-in mice, and muscular activities were recorded before and after trihexyphenidyl administration. RESULTS: (1) Consistent with DYT1 dystoniapatients, Dyt1 knock-in mice showed sustained contractions and co-contractions of the antagonistic bicep femoris and rectus femoris. (2) The abnormal muscle contractions were normalized by trihexyphenidyl. CONCLUSION: The results suggest that the motor deficits in Dyt1 knock-in mice are likely produced by abnormal muscle contractions, and Dyt1 knock-in mice can potentially be used as a manifesting disease model to study pathophysiology and develop novel therapeutics.
Authors: Mai T Dang; Fumiaki Yokoi; Chad C Cheetham; Jun Lu; Viet Vo; David M Lovinger; Yuqing Li Journal: Behav Brain Res Date: 2011-10-08 Impact factor: 3.332
Authors: Xandra O Breakefield; Anne J Blood; Yuqing Li; Mark Hallett; Phyllis I Hanson; David G Standaert Journal: Nat Rev Neurosci Date: 2008-03 Impact factor: 34.870
Authors: Miklos Argyelan; Maren Carbon; Martin Niethammer; Aziz M Ulug; Henning U Voss; Susan B Bressman; Vijay Dhawan; David Eidelberg Journal: J Neurosci Date: 2009-08-05 Impact factor: 6.167
Authors: Lin Zhang; Fumiaki Yokoi; Yuan-Hu Jin; Mark P DeAndrade; Kenji Hashimoto; David G Standaert; Yuqing Li Journal: PLoS One Date: 2011-03-29 Impact factor: 3.240
Authors: Fumiaki Yokoi; Janneth Oleas; Hong Xing; Yuning Liu; Kelly M Dexter; Carly Misztal; Melinda Gerard; Iakov Efimenko; Patrick Lynch; Matthew Villanueva; Raul Alsina; Shiv Krishnaswamy; David E Vaillancourt; Yuqing Li Journal: Neurobiol Dis Date: 2019-10-13 Impact factor: 5.996
Authors: Jesse C DeSimone; Marcelo Febo; Priyank Shukla; Edward Ofori; Luis M Colon-Perez; Yuqing Li; David E Vaillancourt Journal: Neurobiol Dis Date: 2016-07-09 Impact factor: 5.996
Authors: Fumiaki Yokoi; Huan-Xin Chen; Janneth Oleas; Mai Tu Dang; Hong Xing; Kelly M Dexter; Yuqing Li Journal: Behav Brain Res Date: 2021-05-24 Impact factor: 3.352
Authors: Yuning Liu; Hong Xing; Wanhui Sheng; Kyle N Singh; Alexandra G Korkmaz; Caroline Comeau; Maisha Anika; Alexis Ernst; Fumiaki Yokoi; David E Vaillancourt; Charles J Frazier; Yuqing Li Journal: Neurobiol Dis Date: 2021-03-20 Impact factor: 7.046
Authors: Fumiaki Yokoi; Mai Tu Dang; Lin Zhang; Kelly M Dexter; Iakov Efimenko; Shiv Krishnaswamy; Matthew Villanueva; Carly I Misztal; Malinda Gerard; Patrick Lynch; Yuqing Li Journal: IBRO Neurosci Rep Date: 2021-06-12